Cara Therapeutics gets Nasdaq extension to Jan 2025 to regain $1 bid price; stock moved to Capital Market

Tvardi Therapeutics, Inc.

Nasdaq granted 180-day extension, until January 27, 2025, to meet minimum $1.00 closing bid price for 10 consecutive business days.
Company's common stock transferred from Nasdaq Global Market to Nasdaq Capital Market effective August 1, 2024.
If compliance not achieved by deadline, Nasdaq will delist; company may appeal to a Nasdaq Hearings Panel.
Company will monitor bid price and consider options including a reverse stock split to regain compliance.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.